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1. Introduction  
Named after the pathologic changes seen in the pancreas, cystic fibrosis (CF) is the most 
common lethal genetic disease in Caucasians, occuring in around 1 in 3000 live births. CF is 
uncommon among Asians (1 in 31,000 live births) and African Americans (1 in 15,000 live 
births) (Maitra & Kumar, 2005). It is caused by disease-causing mutations on both cystic 
fibrosis transmembrane conductance regulator (CFTR) alleles. Acute, recurrent-acute  and 
chronic pancreatitis in association with CFTR mutations can develop in the setting of either 
CF disease or CFTR-related pancreatitis, which belong within the spectrum of disorders 
associated with CFTR dysfunction.  
2. Cystic fibrosis (mucoviscidosis)  
Cystic fibrosis was historically considered to be a multi-system disease which manifested 
clinically either at birth (with intestinal obstruction due to meconium ileus) or in 
infancy/early childhood (with failure to thrive due to pancreatic insufficiency and 
recurrent/chronic sino-pulmonary disease). Our understanding of this disease has changed 
in recent times, particularly after the discovery of the CFTR gene. Any one, or all of the 
manifestations of CF can occur at any point, from before birth through to childhood, 
adolescence and even in adulthood. 
The CFTR gene responsible for CF is located on chromosome band 7q31.2, and encodes for a 
cyclic adenosine monophosphate (cAMP)-dependent chloride channel (Fig. 1). This 
particular chloride channel is located in the apical membrane of secretory and absorptive 
epithelium of the pancreas, intestine, liver, airway, vas deferens and sweat glands. The 
manifestations of CF generally arise from ductal and glandular obstruction due to an 
inability to hydrate macromolecules within the ductal lumen.  
3. Pancreatic diseases associated with CF and CFTR-related diseases 
Immunohistologic and pathologic studies have identified localisation of CFTR protein at the 
apical domain of the pancreatic ductal cells. Obstruction of proximal intralobular ducts by 
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inspissated protein plugs (obstructive tubulopathy) has been shown as early as during the 
in-utero period in CF (Oppenheimer & Esterly, 1976). The susceptibility of the pancreas to 
intraductal obstruction resulting from CFTR dysfunction is thought to be due to the high 
macromolecule concentration of the secretions and the dependence on the CFTR chloride 
(and bicarbonate) channel for maintaing fluid balance. Progressive ductal obstruction and 
fibrosis of acinar tissue presents as pancreatic insufficiency either at birth or in early 
childhood (Waters et al. 1990). Complete pancreatic exocrine deficiency is the seen in 85% to 
90% of patients with CF (Durno et al., 2002; Ooi et al., 2011a).  
 
 
 
 
Fig. 1. Schema illustrating the processing, structure and function of the CFTR protein. The 
classes of genetic mutations (discussed later) and their effects on the CFTR 
processing/function are illustrated. The CFTR protein consists of two transmembrane 
domains, two nucleotide-binding domains (NBD), and a regulatory R domain. Normal 
functioning involves an agonist such as acetyl-chloine binding to epithleial cells, resulting in 
an increase in cAMP, which activates protein kinase A (PKA). PKA phosphorylates the 
CFTR protein at the R domain, thus resulting in opening of the chloride (Cl¯) channel. ATP, 
adenosine triphosphate; c-AMP, cyclic adenosine monophosphate; CFTR, cystic fibrosis 
transmembrane conductance regulator. 
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The majority of CF patients carrying functionally severe mutations on both alleles (Class I-III 
and VI) have a pancreatic insufficient (PI) phenotype (85% to 90%). A small proportion (2-
3%) of patients carrying severe mutations on both alleles are pancreatic sufficient (PS) at 
diagnosis, but most experience gradual transition from PS to PI (Waters et al.,1990; 
Wilschanski & Durie, 2007). It is well established that PS-CF patients, who are often 
diagnosed at an older age, with more subtle disease manifestations, have mean sweat 
chloride values that are significantly lower than the current diagnostic reference criteria of 
60 mmol/L (Farrell et al., 2008; Gilljam et al., 2004). Without sufficient enzyme activity (or 
enzyme replacement), PI patients suffer from malabsorption of proteins, fats and fat-soluble 
vitamins, and to a lesser extent, carbohydrates. Clinical manifestations of PI include: 
steatorrhoea, failure to thrive/poor weight gain, abdominal distension, a reduction in 
subcutaneous fat and muscle tissue, and fat-soluble vitamin deficiencies. In adolescents, 
absence of a pubertal growth spurt and delayed maturation may occur (Rosenstein, 2006).  
With the increasing life expectancy of CF patients, it has become recognised that a 
significant proportion of PI-CF patients develop glucose intolerance, and up to 32% of 
patients over 25 years of age progress to insulin-requiring CF-related diabetes mellitus 
(Moran et al., 1999; Rosenstein, 2006). CF-related diabetes is characterised by an insidious 
onset and mild clinical course (e.g. gradual weight loss).  
4. Pancreatitis in CF and CFTR-related disease: Pathogenesis 
Pancreatitis is a well-known but uncommon manifestation in CF disease. This is not 
surprising as the majority of patients who carry functionally severe mutations on both 
alleles are PI. Since the presence of residual pancreatic acinar tissue is necessary for 
pancreatitis to occur, symptomatic pancreatitis does not (or rarely) occur in PI patients, but 
is not uncommon in PS-CF patients. Approximately 20% of PS-CF patients develop 
pancreatitis (Ooi et al., 2011a). Several studies have shown that individuals with idiopathic 
recurrent-acute or chronic pancreatitis have an increased incidence of mutations in the CFTR 
gene (Bishop et al., 2005; Cohn et al., 1998; Sharer et al.,1998). Bishop et al. (2005) showed 
that 43% and 11% of patients with idiopathic recurrent-acute or chronic pancreatitis carried 
at least one, and two CFTR mutations (and/or variants), respectively; the diagnostic criteria 
of CF could be fulfilled in 21% of these patients.  
Whilst obstructive tubulopathy of the pancreas due to CFTR dysfunction is thought to be 
primary pathogenic factor, the exact mechanism of pancreatitis associated with CFTR 
mutations is still unknown. Based on murine models, CFTR dysfunction may also affect 
pancreatic acinar cells by impairing apical endocytosis through diminished ductal 
bicarbonate secretion and subsequently reduced alkalinization of the acinar lumen 
(Freedman et al., 2001). A recent study also suggests an important role of pH dysregulation 
in the development of pancreatitis.  Co-release of protons (H+) with proteins from secretory 
granules of acinar cells during pancreatic secretion was demonstrated (Behrendorff et al., 
2010). Acidification of the pancreatic lumen led to a loss of tight junction integrity, which 
allowed the leakage of zymogens into the interstitial fluid. Abberant activation of calcium 
channels may also occur and result in the release and premature activation of zymogens, 
thus causing tissue damage and inflammation. The findings of this study fits with the 
development of pancreatitis in the setting of CFTR mutation(s) or CFTR dysfunction; 
reduced CFTR function impairs entry of bicarbonate into the ducts, and results in a more 
acidic and dehydrated pancreatic lumen. These studies support the complex interactions 
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that exist between the ductular and acinar components of the pancreas in the development 
of pancreatitis. 
Parodoxically, CFTR genotypes associated with otherwise mild phenotypic effects have a 
greater risk of causing pancreatitis, when compared with genotypes associated with 
moderate to severe disease phenotypes. Patients with enough functional CFTR to confer a 
phenotypically functional pancreas have an increased risk of pancreatitis, as sufficient 
pancreatic acinar tissue is required for obstructive ductal lesions to cause disease (Fig. 2).  
 
 
Fig. 2. Risk of pancreatitis in relation to severity of CFTR dysfunction. **The gradient within 
the pancreatitis curve reflects the relative risk of pancreatitis. A delicate balance between the 
degree of residual acinar tissue present and severity of ductal obstruction exists, and this 
balance correlates to the risk of pancreatitis. A. Patients with severe CFTR dysfunction have 
minimal/no risk of developing clinical pancreatitis despite severe ductal obstruction, as 
there is insufficient residual pancreatic acinar tissue. B. The risk of pancreatitis increases 
with decreasing CFTR dysfunction and is highest when there is adequately pathogenic 
ductal obstruction and sufficient residual acinar tissue present. C. With further increases in 
CFTR function, the degree of ductal obstruction is minimal, thus the risk of pancreatitis is 
low despite large amounts of pancreatic acinar tissue. The exception to this is when non-
CFTR modifier factors play a role. CFTR, cystic fibrosis transmembrane conductance 
regulator; Duct Obst., degree of ductal obstruction; f(acinii), residual acinar function; PI, 
pancreatic insufficient.  
5. CFTR mutations 
Since the discovery of the CFTR gene in 1989, advances in molecular analysis techniques 
have identified > 1800 CFTR mutations (Dorfman, 2011). Mutation in this context simply 
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refers to a molecular alteration in the DNA sequence of a gene, with no inference made 
concerning the effect of this alteration on gene expression, protein function and, therefore, 
clinical phenotype. For many of the CFTR mutations which have been identified, the effect 
of the mutation on gene expression or function of the protein product is unknown. This is 
especially true for missense mutations (a base pair substitution in the DNA sequence) which 
represent approximately 40% of the identified mutations. To explain the use and 
interpretation of CFTR mutation analysis in clinical practice, the European Cystic Fibrosis 
Society (ECFS) published a consensus paper in 2008 which categorised mutations into four 
groups based on their predicted clinical consequences: (i) CF-causing mutations, (ii) 
mutations associated with CFTR-related disease, (iii) mutations with no known clinical 
consequence, and (iv) mutations with unknown clinical relevance (Castellani et al., 2008). 
Mutations which are associated with both PS and PI phenotypes are listed in Table 1. Note 
the more conservative list of mutations which are included on the recommended panel of 
CF-causing mutations for population screening developed by the American College of 
Medical Genetics (Farrell et al., 2008). This list is not entirely exhaustive, as other mutations 
can be predicted to be CF-causing if the molecular alteration results in a change in amino 
acid sequence that: severely affects CFTR synthesis and/or function; introduces a premature 
termination signal; or alters invariant nucleotides of intron splice sites. However, the vast 
majority of known mutations do not fulfill the accepted criteria for CF-causing mutations 
(Castellani et al., 2008; Farrell et al., 2008). 
In CF, disease-causing mutations are often identified on newborn screening panels. In recent 
times, several diseases that resemble CF at an organ-specific level (e.g. pancreatitis,  
bronchiectasis and obstructive azoospermia) have also been found to be strongly associated 
with mutations in the CFTR gene (Ooi et al., 2010b). The functional consequence(s) of many 
CFTR gene alterations is unknown and unable to be determined. This is due to the interplay 
of mild and severe mutations, as well as the variation in genotype-phenoytpe expression, 
which is affected by non-CFTR modifiers (genetic and/or environmental).  
The complex and heterogenous presentation of CF disease and CFTR-related disorders is 
associated with a continuous spectrum of CFTR dysfunction. A clear relationship between 
the number and functional severity of CFTR gene alterations, with the range of CFTR-
mediated ion channel abnormalities has been established (Bishop et al., 2005; Wilschanski, 
2006). This observation has helped develop our understanding of the threshold of CFTR-
mediated ion channel function that is required for disease pathogenesis and diagnosis. 
A 5-class classification system for CFTR mutations was originally developed to categorize 
the molecular characteristics of different mutations (Fig. 3) (Tsui, 1992). On the basis of its 
molecular defect, mutations in Classes I-III could be predicted to have severe functional and 
phenotypic consequences. Conversely, Classes IV-V may confer residual CFTR function and 
thus, be predicted to be associated with milder phenotypic consequences. Remarkably, 
genotype-phenotype studies demonstrated an excellent correlation between Classes I-III 
with a PI phenotype, and Classes IV-V with a PS phenotype (Ahmed et al., 2003; Kristidis et  
al.,1992). A 6th mutation class has subsequently been proposed which is also associated with 
severe functional and phenotypic consequences. In general, patients homozygous or 
compound heterozygous for severe mutations (class I-III, and VI) will be PI. Alternatively, 
patients with at least one mild mutation (class IV or V), will often be PS, as the milder of the 
two mutations confers a dominant phenotypic effect. In very young infants, CFTR genotype 
may not be closely associated with pancreatic phenotype; particularly those identified by 
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newborn screening. This is almost certainly due to the fact that some infants carrying severe 
mutations on both alleles have some residual exocrine pancreatic function at birth. 
However, almost all of the patients who are homozygous or compound heterozygous for 
severe mutations will develop PI within the first two years of life (Waters et al., 1990). 
 
CFTR mutations and their associated clinical consequences 
Association Mutations Phenotype 
CF-causing F508del* 
R553X* 
R1162X* 
R1158X 
2184delA* 
2184insA 
3120+1G>A* 
I507del* 
1677delTA 
6542X* 
G551D* 
W1282X* 
N1303K* 
621+1G>T* 
1717-1G>A* 
1898+1G>T* 
R560T* 
G85E* 
711+1G>T* 
1898+1G>A 
S549N 
E822X 
1078delT 
2789+5G>A* 
3659delC* 
Usually 
PI 
A455E* 
R334W* 
R347P* 
711+3A>G 
3849+10kbC>T* 
R117H-T5* 
D1152H 
L206W 
TG13-T5 
Usually 
PS 
CFTR-related 
disease 
R117H-T7* 
D1152H 
TG13-T5 
D565G 
TG12-T5 
S997F 
R297Q 
L997F 
G576A 
TG11-T5 
R74W-D1270N 
R668C-G576A-
D443Y 
M9521 
Usually 
PS 
No clinical 
consequences 
I148T 
R75Q 
875+40A/G 
M470V 
E528E 
T854T 
P1290P 
2752-15G/C 
I807M 
1521F 
F508C 
I506V 
TG11-T5 
- 
Unknown or 
uncertain clinical 
consequence 
Mainly missense mutations with subclinical molecular 
consequences (e.g. M470V), which may co-segregate on 
the same chromosome and exert a more potent, 
cumulative phenotypic effect. 
- 
Table 1. List of CFTR mutations with their associated clinical consequence(s) and pancreatic 
exocrine phenotype(s). Adapted from Castellani et al., 2008. Underlined are the mutations 
associated with both PS and PI phenotypes. * The CFTR mutations included on the 
recommended panel of CF-causing mutations for population screening (Farrell et al., 2008). 
CF, cystic fibrosis;  CFTR, cystic fibrosis transmembrane conductance regulator; PI, 
pancreatic insufficient; PS, pancreatic sufficient.  
Although this class system is useful as a conceptual framework, it does have several 
limitations which include (Ooi et al., 2010b): (i) molecular changes of different mutations 
within the same class (especially classes IV and V), may have varying functional 
consequences, (ii) mutations may have overlapping molecular defects which may be 
assigned to more than one class, (iii) the molecular consequences of the majority of rare 
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CFTR mutations, particularly missense alterations are unknown or cannot be predicted, and 
(iv) inferred properties of many mutations remain to be confirmed by functional studies. 
 
Normal 
 
Normal CFTR protein function 
I 
Defective protein synthesis: Nonsense or frameshift mutations 
associated with a complete lack of CFTR protein at the apical 
membrane (e.g. G542X, 394delTT and 1717-1G>A) 
II 
Abnormal protein folding, processing, and trafficking: 
Misfolded functional CFTR protein is largely degraded 
intracellularly, so there is a complete lack of CFTR protein at the 
apical membrane (e.g. F508del and N1303K) 
III 
Defective regulation: Mutations prevent channel activation by 
inhibiting binding and hydrolysis of ATP at one of the two 
nucleotide-binding domains. Thus the CFTR protein on the apical 
surface is nonfunctional (e.g. G551D) 
IV 
Decreased conductance: Abnormal anion conductance results in 
impaired protein function (e.g. R117H and R347P) 
V 
Reduced abundance: Abnormal splicing, promoter mutations or 
inefficient trafficking results in a reduced number of normally 
functioning protein at the apical membrane (e.g. A455E and 
3849+10kbC>T) 
VI 
Decreased stability or altered regulation of separate ion 
channels: Mutations which cause inherent lability of the CFTR 
protein or alter regulation of other ion channels 
Fig. 3. Classes of CFTR mutations according to the functional consequences of the gene 
product with respect to chloride regulation. Severe mutations (classes I-III and VI) confer 
little or no functional CFTR at the apical membrane, whilst mild mutations (classes IV and 
V) confer some partial CFTR function. Adapted from Tsui, 1992; Wilschanski & Durie, 
2007.CFTR, cystic fibrosis transmembrane conductance regulator. 
A new surrogate measure for the severity of CFTR mutations, known as the Pancreatic 
Insufficiency Prevalence (PIP) score, was recently developed and validated (Dorfman et al., 
2010; Ooi et al., 2011a). The PIP scoring system permitted a more refined classification of the 
functional severity of CFTR mutations, and in a far greater number of patients than previous 
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methods of classification. The PIP score is based upon a direct assessment of the effect of 
each genotype on exocrine pancreatic phenotype; which had been objectively determined in 
a large population-based CF database. This classification system is based on several 
premises: (i) the well-established correlation between severity of CFTR mutations and 
exocrine pancreatic function, (ii) the dominant phenotypic effect conferred by the milder of 
the 2 CFTR mutations, and (iii) the availability of a comprehensive database containing large 
numbers of CF patients, with stringent determination of clinical diagnosis and exocrine 
pancreatic status. Ooi et al. (2011a) described how mutations can be classified as either mild 
(≤0.25) or moderate-severe (>0.25) on the basis of the PIP score (Table 2). 
 
Pancreatic Insufficiency Prevalence (PIP) Scores for Common, Well-Defined  
CFTR Mutations 
Mutation Class Total PI Total PI + PS PIP Score Phenotype 
R117H 
3849+10kbC>T 
R334W 
IV-V 
IV-V 
IV-V 
1 
2 
1 
25 
22 
10 
0.04 
0.09 
0.10 
Mild 
2789+5G>A 
A455E 
G85E 
G551D 
R1162X 
N1303K 
W1282X 
1717-1G>A 
F508del 
G542X 
I507del 
R553X 
711+1G>T 
621+1G>T 
IV-V 
IV-V 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
6 
18 
16 
59 
12 
45 
19 
20 
1276 
74 
11 
24 
36 
96 
16 
37 
22 
67 
13 
48 
20 
21 
1324 
75 
11 
24 
36 
96 
0.38 
0.49 
0.73 
0.88 
0.92 
0.94 
0.95 
0.95 
0.96 
0.99 
1.00 
1.00 
1.00 
1.00 
Moderate-
severe 
Table 2. PIP scores for common, well-defined CFTR mutations based on the prevalence of PI 
in a large and well-defined cohort of Canadian CF patients (n=2481) (Ooi et al., 2011a). The 
PIP score for a specific mutation is the ratio between the PI patients carrying the mutation 
(Total PI), and all PI and PS patients (Total PI + PS) carrying the same mutation when in a 
homozygous state or heterozygous combination with F508del, G551D or class I mutations 
(bona fide severe mutations). For example, a ratio of 1.00 indicates that all patients with 
621+1G>T are PI. Similarly, a ratio of 0.1 demonstrates that 10% of subjects with R334W are 
PI. CFTR, cystic fibrosis transmembrane conductance regulator; PI, pancreatic insufficient; 
PIP, pancreatic insufficiency prevalence; PS, pancreatic sufficient.  
Using the PIP score, a relationship between severity of CFTR genotypes with risk of 
pancreatitis was observed among PS-CF patients. Patients with genotypes associated with 
mild phenotypic (PIP score ≤ 0.25) effects have a greater risk of developing pancreatitis than 
patients with genotypes associated with moderate-severe phenotypes (PIP score > 0.25); 
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among the patients who developed pancreatitis, 70% had a mild genotype, while 30% 
carried a moderate-severe genotype (P = 0.004) (Ooi et al., 2011a). The genotype associated 
with mild PIP scores had a hazard ratio of 2.4 for pancreatitis (95% confidence interval, 1.3-
4.5; P = 0.006). Furthermore, there was a gradation of risk of developing pancreatitis 
according to severity of each allele carried: highest risk seen in CF patients who carried 2 
mild mutations (mild/mild) followed by those who carried 1 mild mutation 
(mild/moderate-severe), compared with those who carried functionally moderate-severe 
mutations on both alleles (Fig. 4). Thus, this is the first systematic study to date, 
demonstrating an association between higher risks of pancreatitis with different degrees of 
genotype mildness (based on the PIP score). 
 
 
Fig. 4. Survival curves (Kaplan-Meier estimate) comparing time to pancreatitis in patients 
grouped according to severity of both CFTR alleles (mild/mild vs. mild/moderate-severe vs. 
moderate-severe/moderate-severe). The survival table (below the curve) indicates the 
number of patients/“survivors“ at risk of pancreatitis at 0, 10, 20, 30, 40 and 50 years 
respectively. Adapted from Ooi et al., 2011a. * Log-rank test CFTR, cystic fibrosis 
transmembrane conductance regulator; Mod-Sev, moderate-severe. 
All classification systems are limited by the fact that the heterogenous CF disease spectrum 
is not just explained by CFTR genotype, but is also influenced by environmental and other 
genetic modifying factors. Genes such as cationic trypsinogen (PRSS1), anionic trypsinogen 
(PRSS2), pancreatic secretory trypsin inhibitor (SPINK1), and chymotrpsinogen C (CTRC) 
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have been demonstrated to be involved in the regulation of trypsinogen autoactivation and 
also play a role in cases of idiopathic recurrent-acute and chronic pancreatitis (Ooi et al., 
2010a). The interactions with environmental factors such as cigarette smoking, alcohol and 
diet are also highly complex, and are only beginning to unravel.  
6. The spectrum of CFTR dysfunction 
The notion of a spectrum of CFTR dysfunction is supported by the observation that CF may 
manifest at different ages, in different organs and with variable severity. Cystic fibrosis and 
CFTR-related disorders comprise of pancreatic exocrine insufficiency, pancreatitis, chronic 
sinopulmonary disease, intestinal diseases, hepatobiliary disease, and obstructive 
azoospermia in men.  
Individuals who carry one or two CFTR gene mutation(s) show an overlapping clinical 
spectrum, ranging from no clinical disease at one extreme, through those with CFTR-related 
disorders, to those with CF disease (with/without sufficient pancreatic function) at the other 
extreme (Fig. 5). 
 
 
 
Fig. 5. Spectrum of disorders associated with the level of CFTR function and the 
respective severity/risk of disease. * Severe CF liver disease with cirrhosis ± portal 
hypertension. CBAVD, congenital absence of the vas deferens; CF, cystic fibrosis; CFTR, 
cystic fibrosis transmembrane conductance regulator; PI, pancreatic insufficient; PS, 
pancreatic sufficient.  
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There is considerable debate and difficulty on where to draw the diagnostic line between CF 
disease and CFTR-related disorder. Although they can be divided into two entities, they 
form part of a continuous spectrum of diseases associated with CFTR dysfunction. Similarly, 
ion channel measurements in the sweat gland (sweat test) and nasal epithelium (nasal 
potential difference test) show a continuum of values with overlap, and no clear delineating 
point between individuals without CF (healthy controls and obligate heterozygotes) and 
patients with CF (pancreatic sufficient and insufficient). Consequently our ability to 
establish or exclude CF disease has become increasingly problematic. 
The subset of clinically heterogeneous patients who are diagnosed with CF in adolescence 
and adulthood, who do not resemble the typical clinical presentation in infancy or early 
childhood are discussed later in this chapter. 
7. Pancreatitis in CF and CFTR-related disorder: Clinical presentation and 
diagnosis  
The initial clinical presentation of acute, recurrent-acute and chronic pancreatitis due to 
CFTR dysfunction can be indistinguishable from idiopathic pancreatitis. The clinical 
features and diagnostic criteria for pancreatitis are covered by companion chapter(s) in this 
textbook. 
The most recent United States Cystic Fibrosis Foundation (USCFF) consensus report (Farrell et 
al., 2008), agreed that a diagnosis of CF can be made in individuals who present with a 
characteristic clinical phenotype or a history of CF in a sibling, in the presence of an abnormal 
sweat chloride value ≥ 60 mmol/L and/or two CF-causing mutations. It is important to note 
that a diagnosis of CF cannot be made based on the identification of CFTR mutations on both 
alleles alone, especially when one or both are not designated as disease-causing mutations. 
Due to the vast array of phenotypes associated with CFTR mutations, the diagnosis of 
patients with CF disease has become increasingly difficult, and the demarcation line 
between those with CF and those not classified as having CF by current diagnostic criteria 
has blurred. To deal with the spectrum of disease, the USCFF consensus report stated that 
the classification of this disease should be limited to two terms (Farrell et al., 2008): (i) CF 
disease, to describe patients who fulfil the currently accepted diagnostic criteria, and (ii) 
“CFTR-related disorder,” to describe individuals with a CF phenotype in at least one 
affected organ plus evidence of CFTR dysfunction, but insufficient to fulfil the diagnostic 
criteria for CF disease (e.g. borderline sweat test and/or 1 – 2 non-CF causing mutation(s)). 
Using this terminology, patients with recurrent-acute or chronic pancreatitis due to CFTR 
dysfunction , may receive a diagnosis of CF pancreatitis or CFTR-related pancreatitis. 
Individuals with a CFTR-related disorder are recognised to be at risk for developing CF disease 
(Farrell et al., 2008). Therefore, a diagnosis of CFTR-related pancreatitis may precede a 
diagnosis of CF, as it may be the initial manifestation of CFTR dysfunction, or it may be 
associated with other CFTR-related disorders at the time of presentation (e.g. infertile males 
with pancreatitis) or later on. Consequently, if repeat sweat chloride values remain in the 
intermediate range (40-59 mmol/L), further assessment has been recommended at a CF care 
center to clarify the diagnosis. Further assessment may include: clinical assessment, 
expanded genetic testing, exocrine pancreatic function testing, and respiratory tract culture 
for CF-associated pathogens. Depending on the clinical presentation, assessment may also 
include ancillary tests, such as pulmonary function testing and urogenital evaluation in 
males (genital examination, rectal ultrasound, and sperm analysis). It is important to 
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emphasise that treatment should be dependent on the disease presentation, and not on 
presence or absence of a diagnostic label. 
7.1 Sweat chloride testing 
The sweat chloride test has been in clinical use for over 50 years, and it still remains the 
principal test for the confirmation of the diagnosis of CF in the genomic era (Gibson & 
Cooke, 1959). Although the test is now commonly available in most diagnostic laboratories, 
appropriate performance of the sweat test in accordance to recommended standards is 
crucial for accurate diagnosis. The sweat test involves transdermal administration of 
pilocarpine by iontophoresis to stimulate sweat gland secretion, followed by collection and 
quantitation of sweat onto gauze or filter paper, or into a Macroduct coil. The reference 
ranges for sweat chloride concentration which we use today, were defined using studies of 
CF patients presenting with classical symptoms of CF at an early age (most were PI); there 
were no “truly healthy” controls, and the technical aspects of the sweat test methodologies 
would not meet currently accepted guidelines (Farrell et al., 2008; Shwachman & 
Mahmoodian, 1967). Furthermore, there has also been no study to accurately determine the 
reference ranges for sweat chloride values in infants and young children less than 5 years of 
age (Farrell et al., 2008). Several studies have also reported patients being diagnosed with 
CF (PS and PI), who have sweat chloride values < 60mmol/L (Desmarquest et al., 2000; 
Highsmith et al., 1994; Stewart et al., 1995). This is especially true among the well described 
CF disease-causing mutations associated with normal or intermediate sweat chloride values 
(e.g. 3849+10kbC>T).  
Sweat chloride values are traditionally interpreted categorically. Due to the aforementioned 
limitations, it is not surprising that the reference values for the various sweat chloride 
categories are not universally agreed upon. According to the USCFF consensus guideline, 
sweat chloride values can be categorised as the following among individuals > 6 months old: 
normal ≤ 39 mmol/L, intermediate 40-59 mmol/L, or abnormal ≥ 60 mmol/L; the 
intermediate range is extended to 30-59 mmol/L in infants up to 6 months old (Farrell et al., 
2008). This differs from the reference ranges recommended by the ECFS: normal ≤ 29 mmol/L, 
intermediate 30-60 mmol/L, and abnormal > 60 mmol/L, for all ages (De Boeck et al., 2006).  
There is preliminary data to suggest that the individual sweat chloride value, taken into 
account with the clinical context, is of more value to the clinician than categorical 
interpretation (Ooi et al., 2011b). This study evaluated the diagnostic performance of sweat 
testing in the general population and in patients with idiopathic pancreatitis who were 
referred to a gastroenterology (GI)-CF clinic. This study raised an important point that 
sweat test parameters and results are dependent on the patient population and disease 
incidence in each population. When comparing the general population to symptomatic 
pancreatitis patients in a GI-CF clinic: the pre-test probability for CF is 1 in 3608 vs. 10%; the 
carrier rate is 4% vs. 50%; and the PI:PS CF ratio is 8:1 vs. all patients with pancreatitis being 
PS (Bishop et al., 2005; Castellani et al., 2010; Dupuis et al., 2005; Durno et al., 2002). It has 
also been reported that a diagnosis of CF can be made in 10% of idiopathic pancreatitis 
patients (referred to a GI-CF clinic), based on sweat testing and/or genotyping, however the 
diagnosis may be equivocal in up to 20% of patients (Bishop et al., 2005; Ooi et al., 2010a). As 
expected, there were vast differences in the diagnostic performance of sweat chloride testing 
in the two populations (Table 3).  
An important observation from this study is the dramatic increase in the positive predictive 
value (PPV) of sweat chloride values ≥ 55 mmol/L in the general population, and the not 
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clinically insignificant high PPV in those who present with symptomatic pancreatitis and 
have sweat chloride values ≥ 40mmol/L (Fig. 6). These results demonstrate how the 
individual sweat chloride result (whilst also taking in to account the clinical context of the 
patient), may be more valuable to the clinician than using the traditional categorical 
interpretation.  
 
 
Fig. 6. PPV of sweat chloride testing in the general population and patients with idiopathic 
pancreatitis referred to a GI-CF clinic (Ooi et al., 2011b).CF, cystic fibrosis; CFTR, cystic 
fibrosis transmembrane conductance regulator; PPV, positive predictive value.  
 
Sw Cl 
(mmol/L) 
General Population GI-CF Clinic 
Sens Spec PPV NPV Sens Spec PPV NPV 
20 100 54 0.1 100 98 48 17 100 
30 99 83 0.2 100 94 77 31 99 
40 98 97 0.9 100 81 91 51 98 
50 97 99 2 100 77 96 70 97 
55 97 100 25 100 73 99 92 97 
60 96 100 100 100 64 100 100 96 
Table 3. Diagnostic performance parameters for various sweat chloride values in a general 
population and patients at a GI-CF clinic. (Ooi et al., 2011b). CF, cystic fibrosis; GI, 
gastroenterology; NPV, negative predictive value; PPV, positive predictive value; Sens, 
sensitivity; Spec, specificity; Sw Cl, sweat chloride.  
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7.2 Genotyping 
Despite the considerable optimism that genotyping would supersede the traditional sweat 
test, there remains considerable misunderstanding of the role of CFTR genotyping as a 
diagnostic aid in CF. In patients with a suspected, but unproven diagnosis of CF, mutation 
testing (including complete sequencing of the CFTR gene) appears to be the least helpful 
diagnostic tool and may be potentially misleading. In fact, carefully performed sweat 
chloride testing has been reported to be more sensitive and specific than complete 
sequencing in patients presenting with a single organ manifestation of CF including 
pancreatitis (Bishop et al., 2005; Gilljam et al., 2004; Wilschanski, 2006). In a cohort of 46 CF 
patients diagnosed in adulthood, only 15 (33%) fulfilled the diagnostic criteria of CF based 
on genotyping alone; all except one of the 15 (6.7%) had an abnormal sweat test > 60 
mmol/L. Sweat testing alone diagnosed CF in 30 (65%) subjects and when sweat testing was 
combined with genotyping, the diagnostic sensitivity only improved slightly to 67% (n=31) 
(Gilljam et al., 2004).  
If a clinician decides to assess a patient’s genotype, it is important to consider that most 
patients presenting in adolescence and adulthood and/or those who present with single-
organ disease, frequently carry one or more rare CFTR mutations which are often not 
included in screening panels. However, extensive genotyping or complete sequencing of the 
CFTR gene has major limitations also. The majority of mutations have unknown functional 
consequences, while some are considered to be benign polymorphisms with no pathogenic 
potential. Furthermore, some mutations are known  to form complex alleles i.e. > 1 mutation 
occurs only on one allele and hence, may be mis-interpreted as the presence of mutations on 
both alleles. With all these variables, there is a potential risk of informing a patient with 
pancreatitis that they have CFTR mutations, and implying they have CF. Misinterpretation 
of genotyping results carries enormous psychosocial and medical implications, as well as 
affecting potential insurability. In a study reporting the outcomes from a commercially 
available extensive CFTR mutation test, 84% of patients identified with 2 CFTR mutations 
were incorrectly labeled as having CF (Keiles & Kammesheidt, 2006; Ooi et al., 2010a). 
7.3 Transepithelial nasal potential difference testing 
The transepithelial nasal potential difference (NPD) test is an electrophysiological test that 
assesses CFTR activity by measuring transepithelial potential difference of the nasal 
epithelium. This test is based on the characteristic bioelectric properties of amiloride-
dependent sodium (Na+) absorption (via ENaC) and CFTR-mediated Cl¯ diffusion (Schuler 
et al., 2004). NPD has been used in CF research for decades but due to a lack of validated 
reference values and standardisation, it has only been cautiously applied in clinical practice 
as an adjunctive test to assist in clarifying the diagnosis of CF, especially for individuals 
with intermediate sweat chloride values (Farrell et al., 2008). 
NPD is measured between a fluid-filled exploring bridge positioned on the nasal respiratory 
mucosa, and a reference bridge inserted into the subcutaneous space. Both bridges are 
linked by Ag/AgCl electrodes (or saturated calomel half-cells) to a high-impedence 
voltmeter. An otoscope is used to help place the tip of the exploring catheter on the 
respiratory mucosa inferior to the concha nasalis inferior. A basal potential difference is 
established once consistent baseline NPD measurements are obtained. Different 
solutions/drugs can be administered via the exploring catheter, and the changes in 
transepithelial potential difference as a response to superfusion can be measured. The 
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findings of a high potential difference during baseline measurements, followed by an absent 
or very low voltage response to zero-chloride plus isoproterenol perfusion, are indicative of 
CF (Knowles et al., 1995).  
Patients who have equivocal sweat chloride results and/or CFTR mutation analysis may 
also have equivocal NPD measurements, and a consensus of what constitutes a borderline 
result is lacking (Ooi et al., 2010b). In addition, the procedure is complex to perform, labour 
intensive, and operator dependent. Although NPD testing has been reported in infants and 
young children, the accurate performance of this test requires undivided cooperation from 
the subject. False positives can occur with incorrect placement of the measuring catheter, 
minor perturbations of nasal epithelium, allergies, respiratory infections, and smoking 
(Cantin et al., 2006).  
7.4 Intestinal ion channel measurement 
Intestinal ion channel measurement (ICM) is an ex vivo test performed in an Ussing 
chamber using a freshly obtained rectal biopsy and measuring its electrical response to a 
series of secretagogues. Intestinal epithelia of CF subjects have been evaluated by two 
different laboratory methods (circulating vs. continuously perfused) (De Jonge et al., 2004; 
Mall et al., 2004). The common finding of both approaches demonstrates absent or 
diminished chloride secretion after stimulation with agonists that act via intracellular cAMP.  
Intestinal ICM has been reported to be useful in clarifying the diagnosis of CF in cases of 
uncertainty, but again the absence of standardisation and well-established reference values 
limits its use in clinical practice (Farrell et al., 2008).  
7.5 Imaging in CF and CFTR-related pancreatitis 
The typical changes of the pancreas on imaging in patients with CF are neither specific nor 
diagnostic for CF and CFTR-related pancreatitis. In CF, fatty replacement of the pancreatic 
parenchyma, with or without glandular atrophy (56-93%) is the most common finding at 
imaging in adult patients, and the mean age of fatty replacement is 17 years (Robertson et 
al., 2006; Shanbhogue et al., 2009). Other radiological findings include pancreatic 
calcifications (7%); cyst formation (pancreatic cystosis); and abnormalities of the pancreatic 
duct, including strictures, beading, dilatation, and obstruction (Shanbhogue et al., 2009). The 
pancreatic duct can be poorly demonstrated with ultrasonography (US) in CF patients with 
pancreatic atrophy and fatty replacement, and is best demonstrated with magnetic 
resonance cholangiopancreatography (MRCP) or endoscopic retrograde 
cholangiopancreatography (ERCP) (Robertson et al., 2006). Imaging has no role in 
monitoring of exocrine pancreatic function but has a yet to-be-defined role in surveillance 
for pancreatic adenocarcinoma.  
8. Management of pancreatitis in CF and CFTR-related disorder 
The management of pancreatitis associated with CF or CFTR mutations per se, is currently 
no different to other forms of pancreatitis (covered in companion chapters). Affected 
patients however should be referred to a CF clinic or gastroenterologist with 
interests/expertise in CF for a thorough evaluation. The main considerations in these 
patients are a progression from PS to PI, and the risk of developing CF disease and/or 
disease in other CF-affected organs (e.g. bronchiectasis) (Gilljam et al., 2004; Ooi et al., 
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2011a). In addition, there are increasing concerns of an increased risk of pancreatic 
adenocarcinoma among those with CF and CFTR-related pancreatitis. 
8.1 Pancreatic function testing 
The exocrine pancreas has a large reserve capacity and requires between 90% and 99% of 
enzyme secretory capacity to be lost before a subject develops clinical manifestations of PI. It 
is recommended that patients with PS-CF and CFTR-related pancreatitis have their 
pancreatic exocrine function assessed. Individuals who have sufficient pancreatic function at 
presentation need to be assessed periodically, or when new symptoms suggestive of PI 
develop, as some may progress to PI (Gilljam et al., 2004; Ooi et al., 2011a). Progression of PI 
is dependent on the following factors: (1) the carriage of moderate-severe mutations on both 
alleles, and (2) the development of symptomatic pancreatitis. PS-CF patients with mild 
genotypes (i.e. those otherwise expected to remain PS) who develop pancreatitis are at an 
increased risk of progressing from PS to PI (odds ratio = 5.5) (Ooi et al., 2011a).  
Exocrine pancreatic function can be measured through non-invasive and invasive methods. 
Currently, non-invasive pancreatic function tests are commonly utilised for defining the 
exocrine pancreatic phenotype. The 72-hour faecal fat balance test, expressed as the 
coefficient of fat absorption (CFA), is considered the gold standard as far as non-invasive 
tests are concerned (Ooi et al., 2010b). However, the test is inconvenient and not well 
tolerated by patients or laboratory staff. Faecal elastase-1 is an alternative indirect stool 
marker for pancreatic function, as elastase (an endogenous pancreatic secretion enzyme) is 
resistant to gastrointestinal degradation. Using a cut-off of 200 μg/g stool, the sensitivity for 
mild, moderate, severe and all patients with PI, was reported to be 63%, 100%, 100% and 
93% respectively, whilst the specificity was 93% (Loser et al., 1996). Because of its ease of 
use, faecal elastase-1 is recommended for evaluating pancreatic function at diagnosis and for 
follow-up monitoring. Currently, a value of < 100 μg/g in individuals over the age of 2 to 3 
years is considered indicative of PI. Values from 100 μg/g to 200 μg/g are associated with 
significant loss of pancreatic function, although not necessarily of sufficient severity to 
confer PI, and warrant the need for pancreatic enzyme supplementation (Farrell et al., 2008). 
In addition, there are differences in the diagnostic performance parameters (sensitivity and 
specificity) between monoclonal and polyclonal assays for faecal elastase; the monoclonal 
assay is superior due to less cross-reactivity and can be used whilst patients are on 
pancreatic enzyme therapy (Pezzilli et al., 2005). False positivity can occur due to 
malabsorption from an intestinal cause, particularly if there is stool dilution from severe 
diarrhoea (Beharry et al., 2002). Other indirect methods for assessing pancreatic function 
include the measurement of faecal concentrations of the pancreatic enzymes, trypsin and 
chymotrypsin. However, both faecal trypsin and chymotrypsin are prone to intestinal 
degradation and faecal chymotrypsin cross-reacts with exogenously administered enzyme 
therapy. 
Serum trypsinogen has been used for newborn screening for more than two decades, and has 
been shown to help define pancreatic functional status in CF patients older than 7 years of age 
(Durie et al., 1986). This test has the added benefit of being able to predict the progression of 
pancreatic status from PS to PI (Couper et al., 1995). Serum trypsinogen is also capable of 
identifying the presence of pancreatic disease and dysfunction (loss of pancreatic reserve or 
pancreatitis) in individuals with a CFTR-related disorder (Ooi et al., 2010b).  
Alternatively, the invasive direct pancreatic stimulation test allows assessment of both 
pancreatic acinar (enzyme) and ductular (electrolyte and fluid) status. There is currently no 
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standardized methodology for direct pancreatic stimulation testing and various techniques 
are used throughout the world. Measurements and diagnosis of exocrine pancreatic status 
based on pancreatic stimulation testing warrants careful interpretation and can be 
misleading if not performed accurately. The quantitative pancreatic stimulation test that 
uses perfusion markers with multiple sampling periods is sensitive, highly specific, and 
capable of evaluating the entire range of pancreatic function (Groman et al., 2004). This 
technique is regarded as the true gold standard in direct pancreatic stimulation testing. 
Nevertheless, this test is time consuming, technically complex to perform and not routinely 
available. Consequently, alternative and simpler direct pancreatic stimulation techniques 
(non-quantitative), are used at many clinical centers. These generally utilise a single-lumen 
duodenal tube or endoscope to aspirate duodenal pancreatic secretions, either as a spot 
sample and/or over a timed sampling period (Choi et al., 2001; Monaghan et al., 2004; 
Rohlfs et al., 2002; Suaud et al., 2007). Despite their popularity, non-quantitative techniques 
have a high false positive rate for misdiagnosing PI and have not been proven superior over 
non-invasive indirect pancreatic function tests. In fact, Schibli et al. (2006) demonstrated that 
these techniques carry the greatest risk of misclassifying a PS patient as PI, especially among 
PS patients with a secretory capacity between the threshold of PI and the lower limit of 
normal (Grody et al., 2001; Schibli et al., 2006). 
8.2 Referral to a CF care centre 
As mentioned previously, CF and CFTR-related disease may manifest with variable 
severity, in single or multiple organs, and at different ages. For the clinician at hand dealing 
with a patient with pancreatitis associated with borderline or abnormal sweat test results 
and/or CFTR mutations, a more detailed assessment of other affected organ systems may be 
necessary. The phenotypic features of CF which should be kept in mind are summarised in 
Table 4. Furthermore, other organs affected by CFTR dysfunction may not be clinically 
evident at the time of diagnosis, thus overall assessment and routine follow-up is crucial. 
Referral should be made to a multidisciplinary CF care centre that can provide 
comprehensive diagnostic testing, determination of involvement of all affected organs (e.g. 
pulmonary disease), timely intervention, disease-specific counseling (e.g. fertility and 
smoking cessation for pancreatitis and lung disease), genetic counseling, and monitoring. 
Beyond the well-established phenotypic features of CF, cystic-fibrosis-related diabetes 
(CFRD) should also be tested for and monitored, particularly among those confirmed as 
having CF and who progress to PI.  
8.3 Prognosis 
Data from the Canadian CF registry shows that the median survival age in patients with CF 
has risen from 29.1 years in 1988 to 46.6 years in 2008 (Canadian Cystic Fibrosis Foundation, 
2008). Similar improvements have occurred in other countries, but differences in survival 
persist (Fogarty, 2000). End-stage lung disease is the primary cause of morbidity and 
mortality in CF, but discussions on the respiratory aspects of CF are beyond the scope of this 
chapter. For patients with CFTR-related pancreatitis, the long-term outcomes are unknown.  
A recent study reported an association between CFTR mutations and a higher risk of 
pancreatic adenocarcinoma (OR 1.82; 95% CI, 1.14-2.94; P = 0.011) (McWilliams et al., 2010). 
Carriers of CFTR mutations were seen to be diagnosed at a younger age than non-carriers, 
with the effect exclusively seen in ever-smokers (median 60 years vs. 65 years; P = 0.028).  
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Phenotypic Features of CF 
Gastrointestinal 
Abnormalities 
i. Pancreatic: PI, recurrent-acute pancreatitis, chronic pancreatitis 
ii. Intestinal: meconium ileus, distal intestinal obstruction syndrome, 
rectal prolapse 
iii. Hepatic: prolonged neonatal jaundice, chronic hepatic disease (focal 
biliary cirrhosis or multilobular cirrhosis) 
iv. Nutritional: failure to thrive, hypoproteinemia and oedema, fat-
soluble vitamin deficiency syndromes 
Male Genital 
Tract Disease 
i. Obstructive azoospermia due to congenital absence of the vas 
deferens 
Chronic 
Sinopulmonary 
Disease 
i. Persistent colonisation/infection with typical CF pathogens 
(Staphylococcus aureus, nontypeable Haemophilus influenza, 
mucoid and nonmucoid Pseudomonas aeruginosa, 
Stenotrophomonas maltophilia, and Burkholderia cepacia) 
ii. Chronic cough and sputum production 
iii. Persistent chest radiographic findings (e.g bronchiectasis, 
atelectasis, infiltrates, and hyperinflation) 
iv. Airway obstruction, with wheezing and air-trapping 
v. Nasal polyps 
vi. Digital clubbing 
Table 4. Phenotypic features of CF. (Adapted from Farrell et al., 2008). CF, cystic fibrosis; PI, 
pancreatic insufficiency.  
9. Areas for future research 
Greater understanding of the true prevalence of CFTR-related disorders, including CFTR-
related pancreatitis is much needed, and long-term studies in these patients are lacking.  
Despite CF being a monogenic disease, the development of pancreatitis in CF and CFTR-
related disorder is dependent on complex interactions with non-CFTR genetic, 
environmental and anatomic factors. Future research is needed to investigate the complex 
interaction between CFTR, other known (e.g. PRSS1 and SPINK1 mutations) and unknown 
genetic factors, and their interplay with environmental factors. Future studies are needed to 
determine the risk and protective modifier factors (genetic and environmental) that lead to 
the different single organ phenotypes in CFTR-related disorders (i.e. “why do individuals 
with the same combinations of CFTR mutations present heterogeneously?”). This in turn 
may also lead to additional therapeutic potentials.  
One such therapeutic potential in the pipeline are small molecule therapies, known as CFTR 
correctors and potentiators. These therapies may have a role in not only patients with CF, 
but also those with CFTR-related pancreatitis; in view of our recent increased understanding 
of the relationship between CFTR dysfunction and risk of pancreatitis (Ooi et al., 2011a). A 
recent study of a CFTR mutation-specific potentiator reported improvement in CFTR 
function (measured using NPD and sweat chloride testing) and lung function in affected CF 
patients with a G551D mutation (Accurso et al., 2010). 
With increased longevity of patients with CF, the relatively infrequent condition of 
pancreatic adenocarcinoma is anticipated to become more clinically relevant. In view of its 
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associated high mortality rates, future studies into optimal screening regimens and 
modalities in patients with genetic causes of chronic pancreatitis are needed. 
10. Conclusion 
There has been a vast expansion in our understanding of the wide range of phenotypes 
associated with CFTR dysfunction since the discovery of the CFTR gene. Pancreatitis is one 
such phenotype, which is almost exclusively seen in patients who are PS. In addition, a 
relationship between the severity of CFTR genotypes and the risk of pancreatitis has been 
established. Paradoxically, genotypes associated with otherwise mild phenotypic effects 
have the greater risk for causing pancreatitis; compared with genotypes associated with 
moderate to severe disease phenotypes.  
Idiopathic acute, recurrent-acute and chronic pancreatitis may be the initial manifestation of 
CF and CFTR-related disorder. However, diagnosing CF or CFTR-related disorder can be 
challenging. Sweat chloride testing is the principal diagnostic test and effectively diagnoses 
CF patients with the severe PI phenotype but it may have a limited ability to conclusively 
establish or exclude a diagnosis of CF disease. Careful interpretation of sweat chloride 
values and repeated testing may be necessary. CFTR genotyping for investigation of 
idiopathic pancreatitis has a limited diagnostic yield, may be misleading and may have 
uncertain “real life” consequence(s). Referral to a tertiary CF centre for further assessment is 
recommended, and periodical reassessment may be necessary to detect, monitor and 
intervene in treatable co-morbidities, even if the diagnostic criteria for CF cannot be fulfilled. 
Development of symptomatic pancreatitis is a strong risk factor for progressive decline in 
exocrine pancreatic function in patients with cystic fibrosis and possibly also in CFTR-
related pancreatitis; thus, it is important to monitor for the development of exocrine 
pancreatic insufficiency over time. 
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